At a glance
- Originator Aventis
- Class Analgesics; Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatic disorders
Most Recent Events
- 17 Feb 1995 Discontinued-Preclinical for Inflammation in France (Unknown route)
- 17 Feb 1995 Discontinued-Preclinical for Rheumatic disorders in France (Unknown route)